U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923162) titled 'MACE and BTK Inhibitors' on Sept. 04.
Brief Summary: Bruton's tyrosine kinase inhibitors (BTKis) have demonstrated substantial therapeutic efficacy across multiple B-cell malignancies. Their durable hematologic benefits confer a favorable benefit-risk profile compared with other treatments, positioning BTKis as a cornerstone of therapy in several B-cell malignancies. However, BTKis are associated with an increased risk of cardiovascular (CV) adverse events, ranging from common complications such as atrial fibrillation (AF) and hypertension to more severe outcomes, including ischemic MACE.
Accumulating evidence suggests that while CV...